Sign in

naultjc.bsky.social

@naultjc.bsky.social
227 followers 236 following 35 posts
PostsRepliesMedia
naultjc.bsky.social @naultjc.bsky.social · 27/11/2025
1) We recently published a multicentric study in cghjournal.org/article/S154... We analyzed using machine learning an international cohort of 1,399 pts treated for HCC with atezo/bev across 12 centers to uncover clinically meaningful subgroups. @etrepo.bsky.social
cghjournal.org
The “A-B-C” classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab
We aimed to identify subgroups of patients with unresectable hepatocellular carcinoma (HCC) using a non‐a priori, data‐driven machine learning approach to uncover subgroups with distinct profiles acro...
122
naultjc.bsky.social @naultjc.bsky.social · 23/11/2025
1) We recently identified as serum tumor biomarker of fibrolamellar carcinoma, procalcitonin, with @zucmanrossi.bsky.social and @markyarchoan.bsky.social that you can find in www.medrxiv.org/content/10.1...
medrxiv.org
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma
Introduction: Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers (alpha-fetoprotein (AFP) and CA19-9). An o...
132
naultjc.bsky.social @naultjc.bsky.social · 20/11/2025
Claudia Campani from Cordeliers Research Center received Best clinical poster award in @ILCAnews meeting in Hong Kong
000
naultjc.bsky.social @naultjc.bsky.social · 20/11/2025
Claudia Campani presenting our work on Molecular based therapy in primary liver cancer refractory to systemic treatments in ILCA meeting in Hong Kong
010
naultjc.bsky.social @naultjc.bsky.social · 16/09/2025
Our work about « Molecular based targeted therapies in primary liver cancers » presented by Claudia Campani at ESMO precision medicine @myesmo.bsky.social
020
naultjc.bsky.social @naultjc.bsky.social · 20/07/2025
Iron Maiden, Paris 2025
030
naultjc.bsky.social @naultjc.bsky.social · 17/07/2025
Kendrick Lamar/SZA Paris 2025
010
naultjc.bsky.social @naultjc.bsky.social · 13/07/2025
Neil Young, Paris 2025
010
Reposted by @naultjc.bsky.social
Nature Genetics @natgenet.nature.com · 08/07/2025
📢ONLINE @natgenet.nature.com 📰Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers. By Tim Arnoldus, Daniel S. Peeper and colleagues. ⬇️ www.nature.com/articles/s41...
nature.com
Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers - Nature Genetics
The paralogs cytidine diphosphate diacylglycerol synthase 1 and 2 form a potentially targetable synthetic lethal relationship in mesenchymal-like cancers that involves disruption of lipid metabolism.
141
naultjc.bsky.social @naultjc.bsky.social · 23/06/2025
Joe Satriani and Steve Vaï, Paris 2025
010
naultjc.bsky.social @naultjc.bsky.social · 19/06/2025
Pr Éric Trepo on genetic prédisposition to HCC on alcohol related liver Disease in the Paris Liver Cancer Group Day, June 2025
010
naultjc.bsky.social @naultjc.bsky.social · 19/06/2025
Paris Liver Cancer Group day, 19 June 2025.
000
naultjc.bsky.social @naultjc.bsky.social · 19/06/2025
Paris Liver Cancer Group day, 19 June 2025.
000
naultjc.bsky.social @naultjc.bsky.social · 30/05/2025
www.nature.com/articles/s41...
nature.com
The pivot penalty in research - Nature
An analysis of millions of scientific papers and patents reveals a ‘pivot penalty’ when researchers shift direction, with the impact of studies decreasing rapidly the further they move from their prev...
000
naultjc.bsky.social @naultjc.bsky.social · 25/04/2025
🧵1/ Can systematic biopsies during RFA improve how we diagnose & manage hepatocellular carcinoma (HCC)? Our study was recently published in J hep reports. Here's what we found 👇 www.jhep-reports.eu/article/S258...
jhep-reports.eu
Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma
We aim to assess the safety and diagnostic/prognostic value of tumor and non-tumor biopsies systematically collected during radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC).
132
Reposted by @naultjc.bsky.social
Rob Brierley @robbrierley.bsky.social · 21/02/2025
Routine [18F]FCH and [18F]FDG PET-CT for tumour staging in all patients with a 1st diagnosis of hepatocellular carcinoma has limited clinical value Guidelines should continue to emphasise morphological imaging (eg MRI & CT) for staging #OncSky #MedSky @oncoalert.bsky.social @naultjc.bsky.social
043
Reposted by @naultjc.bsky.social
The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 21/02/2025
New research - Nault et al - [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study buff.ly/419ebHP #MedSky #OncSky #LiverSky @naultjc.bsky.social
Summary of research findings and their implications
021
naultjc.bsky.social @naultjc.bsky.social · 04/02/2025
www.thelancet.com/journals/lan...
thelancet.com
Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials
Common Sense Oncology (CSO) prioritises treatments providing meaningful benefits for people with cancer. Here, we describe CSO principles aimed at improving the design, analysis, and reporting of rand...
010
naultjc.bsky.social @naultjc.bsky.social · 16/01/2025
Fire walk with him
010
Reposted by @naultjc.bsky.social
Rob Brierley @robbrierley.bsky.social · 15/01/2025
New research - Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial www.thelancet.com/journals/lan... #GastroSky #OncSky #MedSky @oncoalert.bsky.social
095
naultjc.bsky.social @naultjc.bsky.social · 19/12/2024
www.nature.com/articles/s41...
nature.com
Engineered extrachromosomal oncogene amplifications promote tumorigenesis - Nature
Large extrachromosomal DNAs are engineered using a CRISPR- and Cre–loxP-based approach and shown to drive cancer in mouse models, with potential applications in determining the role of oncogene a...
000
naultjc.bsky.social @naultjc.bsky.social · 02/12/2024
www.nature.com/articles/s41...
021
naultjc.bsky.social @naultjc.bsky.social · 23/11/2024
aacrjournals.org/clincancerre...
000